백혈구 증가증 시장 보고서(2025년)
Leukocytosis Global Market Report 2025
상품코드 : 1760592
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,501,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,396,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,292,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

백혈구 증가증 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 자기 면역 질환과 같은 만성 질환의 유병률 증가, 조기 및 정확한 진단 솔루션에 대한 수요 증가, 면역계 기능 장애에 빠지기 쉬운 노인 인구 증가, 조기 발견으로 이어지는 의식 증가 및 정기의 건강진단, 세계의 헬스케어 지출의 전체적인 증가 등, 여러 요인에 기인하고 있습니다. 예측기간 중에 예상되는 주요 동향에는 진단 툴에의 인공지능의 통합, 휴대형 포인트 오브 케어 백혈구 계수 장치의 개발, 원격 환자 모니터링을 위한 원격 의료 플랫폼의 채용, 자동 백혈구 계수 기술의 발전 등이 있습니다.

혈액 관련 질환 증가는 향후 몇 년간의 백혈구 증가증 시장의 성장을 가속할 것으로 예측되고 있습니다. 특히 고령화에 의해 상승하고 있습니다. 고령자는 면역 시스템의 약체화나 건강 합병증의 축적에 의해 빈혈, 백혈병, 응고 장애 등의 상태에 빠지기 쉽기 때문입니다. 혈구 증가증의 중요한 지표가 되고 있습니다. 이것은 조기 발견의 개선, 모니터링 솔루션의 개선, 보다 효과적인 치료 방법의 필요성을 강조하고 있습니다. 2024년 미국에 본사를 둔 암 단체인 미국암학회는 2024년에 6만 2,770건의 백혈병의 신규 사례를 보고했으며, 2023년 5만 9,610건에서 현저한 증가했다고 보고했습니다.

백혈구 증가 시장의 주요 기업은 질병의 조기 발견을 개선하고 진단 정확도를 높이고 맞춤 치료 전략을 지원하기 위해 진단 플랫폼에 인공지능을 통합하는 움직임을 강화하고 있습니다. 머신러닝, 딥러닝, 자연 언어 처리 등의 기술을 활용하여 의료 데이터를 해석하고 질병 진단을 지원하거나 자동화합니다. Koninklijke Philips NV는 CT 5300 시스템을 발표했습니다. 이 시스템은 독특한 AI 기술을 통합하여 컴퓨터 단층 촬영(CT) 이미지 처리 프로세스를 최적화합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장의 거시경제 시나리오: 금리, 인플레이션, 지정학, 무역 전쟁 및 관세, 코로나 및 회복이 시장에 미치는 영향을 포함

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 : 경쟁 벤치마킹 대시보드

제33장 주요 기업 합병·인수(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가·부문과 전략

제36장 부록

SHW
영문 목차

영문목차

Leukocytosis is a condition characterized by an elevated white blood cell (WBC) count in the bloodstream, often indicating an underlying infection, inflammation, or immune response. The primary purpose of treating this condition is to strengthen the body's defense mechanisms by increasing the number of WBCs to combat infections or heal injuries.

The main types of diseases associated with leukocytosis include infections, inflammation, leukemia, and stress response. Infections trigger leukocytosis as the immune system responds to invading pathogens by boosting the production of white blood cells (particularly neutrophils) to combat bacterial threats. Diagnosis of leukocytosis typically involves blood tests, bone marrow biopsies, and imaging techniques. The condition is managed and treated through various distribution channels, such as hospital pharmacies, online pharmacies, and retail pharmacies. Key end users of leukocytosis-related diagnostics and treatments include hospitals, diagnostic laboratories, and research institutions.

The leukocytosis market research report is one of a series of new reports from The Business Research Company that provides leukocytosis market statistics, including leukocytosis industry global market size, regional shares, competitors with an leukocytosis market share, detailed leukocytosis market segments, market trends and opportunities, and any further data you may need to thrive in the leukocytosis industry. The leukocytosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The leukocytosis market size has grown strongly in recent years. It will grow from $4.89 billion in 2024 to $5.17 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth during the historic period can be attributed to several factors, including the increasing incidence of infections and inflammatory diseases, rising awareness and diagnosis of blood disorders, a higher prevalence of leukemia and other cancers, a growing aging population susceptible to immune dysfunction, and an increase in hospital admissions for chronic illnesses.

The leukocytosis market size is expected to see strong growth in the next few years. It will grow to $6.39 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The projected growth during the forecast period can be attributed to several factors, including the increasing prevalence of chronic illnesses such as cancer and autoimmune diseases, the rising demand for early and precise diagnostic solutions, a growing elderly population prone to immune system dysfunction, heightened awareness and routine health check-ups leading to early detection, and the overall increase in global healthcare spending. Key trends expected during the forecast period include the integration of artificial intelligence into diagnostic tools, the development of portable point-of-care leukocyte count devices, the adoption of telemedicine platforms for remote patient monitoring, advancements in automated leukocyte counting technologies, and the use of digital health records to enable personalized treatment strategies.

The increasing occurrence of blood-related disorders is anticipated to drive the growth of the leukocytosis market in the coming years. These disorders involve medical conditions that impact the components of blood, including red and white blood cells, platelets, and plasma. The prevalence of such diseases is rising, particularly due to aging populations, as older individuals are more prone to conditions such as anemia, leukemia, and clotting disorders because of weakened immune systems and accumulated health complications. These disorders frequently result in elevated white blood cell counts-a key indicator of leukocytosis-underscoring the need for improved early detection, better monitoring solutions, and more effective treatment methods. For example, in 2024, the American Cancer Society, a US-based cancer organization, reported 62,770 new cases of leukemia, marking a notable increase from 59,610 cases in 2023. Consequently, the increasing prevalence of blood-related diseases is fueling the growth of the leukocytosis market.

Leading companies in the leukocytosis market are increasingly incorporating artificial intelligence into diagnostic platforms to improve early disease detection, enhance diagnostic precision, and support personalized treatment strategies. AI-powered diagnostic tools utilize technologies such as machine learning, deep learning, and natural language processing to interpret medical data and aid in or automate disease diagnosis. For instance, in December 2024, Koninklijke Philips NV, a healthcare firm based in the Netherlands, introduced the CT 5300 system. This system integrates proprietary AI technologies to optimize computed tomography (CT) imaging processes. It includes the CT smart workflow, which features AI-powered tools such as Precise Position, Precise Cardiac, and Precise Brain to streamline scan setup, increase diagnostic accuracy, and minimize radiation exposure.

In February 2024, AbbVie Inc., a US-based biopharmaceutical company, completed the acquisition of ImmunoGen Inc. for an undisclosed sum. This strategic move bolsters AbbVie's oncology pipeline by incorporating ImmunoGen's specialized capabilities in antibody-drug conjugates (ADCs), enhancing the company's efforts to develop targeted treatments for blood-related cancers and conditions such as leukocytosis. ImmunoGen Inc. is a biotechnology company based in the US that focuses on ADCs for treating blood cancers, including leukemia, which frequently leads to leukocytosis.

Major players in the leukocytosis market are McKesson Corporation, Pfizer Inc., Johnson & Johnson, Siemens Healthineers AG, Roche Diagnostics AG, Bristol Myers Squibb, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis International AG, Danaher Corporation, Merck KGaA, Becton, Dickinson and Company (BD), Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics, Agilent Technologies Inc., Grifols SA, Hologic Inc., Illumina Inc., PerkinElmer Inc., Sysmex Corporation, Beckman Coulter Diagnostics Inc, Bio-Rad Laboratories, Bio-Techne Corporation, NeoGenomics Laboratories, Inc., DiaSorin S.p.A., DiaSorin S.p.A.

North America was the largest region in the leukocytosis market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in leukocytosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the leukocytosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The leukocytosis market includes revenues earned by entities through complete blood count (CBC) testing, white blood cell differential analysis, monitoring and management of underlying conditions, development and administration of targeted therapeutics, and support for clinical research and drug trials focused on hematologic abnormalities. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Leukocytosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on leukocytosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for leukocytosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The leukocytosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Leukocytosis Market Characteristics

3. Leukocytosis Market Trends And Strategies

4. Leukocytosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Leukocytosis Growth Analysis And Strategic Analysis Framework

6. Leukocytosis Market Segmentation

7. Leukocytosis Market Regional And Country Analysis

8. Asia-Pacific Leukocytosis Market

9. China Leukocytosis Market

10. India Leukocytosis Market

11. Japan Leukocytosis Market

12. Australia Leukocytosis Market

13. Indonesia Leukocytosis Market

14. South Korea Leukocytosis Market

15. Western Europe Leukocytosis Market

16. UK Leukocytosis Market

17. Germany Leukocytosis Market

18. France Leukocytosis Market

19. Italy Leukocytosis Market

20. Spain Leukocytosis Market

21. Eastern Europe Leukocytosis Market

22. Russia Leukocytosis Market

23. North America Leukocytosis Market

24. USA Leukocytosis Market

25. Canada Leukocytosis Market

26. South America Leukocytosis Market

27. Brazil Leukocytosis Market

28. Middle East Leukocytosis Market

29. Africa Leukocytosis Market

30. Leukocytosis Market Competitive Landscape And Company Profiles

31. Leukocytosis Market Other Major And Innovative Companies

32. Global Leukocytosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Leukocytosis Market

34. Recent Developments In The Leukocytosis Market

35. Leukocytosis Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기